Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989
Average monthly antibiotics cost during 26-month, post-intervention period was $7,600 less than in 16-month pre-policy period (p<0.001). Therapies altered by ID 34.5% of cases during 26-month period. Antibiotic use per patient in similar DRG decreased by 24% (p=0.005) and cost decreased by 32% (p=0.004). In respiratory infections, DRG average number of doses decreased by 33% and cost by 45% (p=0.05 and 0.04 respectively). Pt outcomes similar pre and post intervention.
Reference:
Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, and O’Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987-1989. American Journal of Medicine. 1991;90:439-444.
Setting:
Palo Alto VA, Palo Alto, CA, USA
Key staff:
infectious disease service
Intervention:
Multidisciplinary – Implementation of new restrictions in antibiotic formulary for broad-spectrum antibiotics and restrictions for antibiotics maximum daily dosage.
Impact:
Average monthly antibiotics cost during 26-month, post-intervention period was $7,600 less than in 16-month pre-policy period (p<0.001). Therapies altered by ID 34.5% of cases during 26 month period. Antibiotic use per patient in similar DRG decreased by 24% (p=0.005) and cost decreased by 32% (p=0.004). In repiratory infections DRG average number of doses decreased by 33% and cost by 45% (p=0.05 and 0.04 respectively). Pt outcomes similar pre and post intervention.
